Autopsy report · NCT05335473

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

“The anticipated efficacy was not achieved; the primary objective of Stage 1 in the Simon-2 design was not met.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 4 months before it stopped.
• 34 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Henan Cancer Hospital

Sponsor type

Government (non-US federal)

Conditions

HR Positive HER2 Negative Advanced Breast Cancer

Interventions

Eribulin and Tucidinostat

Participants

34

Sites

1

Countries

China

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.